
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ernest G. HOPE	Attorney Docket No.: HOPEP002
Application No.: 09/722,096	Examiner: Christopher H. YAEN
Filed: 11/22/2000	Art Unit: 1643 Confirmation No.: 4236
Title: ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER THERAPY	

**INFORMATION DISCLOSURE STATEMENT
BEFORE FINAL ACTION OR NOTICE OF ALLOWANCE
37 CFR §§ 1.56 AND 1.97(c)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The references identified in the attached Form PTO-1449, copies of which are attached, may be material to examination of the above-identified patent application. Applicant identifies these references in compliance with his duty of disclosure pursuant to 37 CFR §§ 1.56 and 1.97. The Examiner is requested to make the identified references of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that the references indeed constitute prior art.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits, or after three months from the filing date of this application, whichever event occurred last, but it is believed before the mailing date of either: (i) a final Action under 37 CFR § 1.113 or (ii) a Notice of Allowance under 37 CFR § 1.311, whichever occurs first.

The Commissioner is hereby authorized to charge the required \$180 fee under 37 CFR §1.17(p) for the filing of this Information Disclosure Statement, and for any additional fee(s) found to be due, to Deposit Account No. 500388 (Order No. HOPEP002).

Respectfully submitted,

BEYER WEAVER LLP

/Emily M. Haliday/

Emily M. Haliday, J.D., Ph.D.
Registration No. 38,903

Customer No. 22434
P.O. Box 70250
Oakland, CA 94612-0250